Drug Profile
BAY 1217389
Alternative Names: BAY1217389Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Bayer
- Class 1 ring heterocyclic compounds; Antineoplastics; Small molecules
- Mechanism of Action Cell death stimulants; TTK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (PO, Capsule)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (PO, Liquid)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Netherlands (PO, Capsule)